Prostate Cell News Volume 17.00 | Jan 9 2025

    0
    35







    2026-01-09 | PCN 17.00


    Prostate Cell News by STEMCELL Technologies
    Vol. 17.00 – 9 January, 2026

    TOP STORY

    Sodium-Glucose Cotransporter 2 Inhibitors for Patients with Prostate Cancer Undergoing Hormone Therapy

    In this cohort study with a target trial emulation design, sodium-glucose cotransporter 2 inhibitor use was associated with delayed hormone therapy failure in patients with prostate cancer, suggesting a potential oncologic benefit beyond glucose lowering.
    [JAMA Oncology]

    Full Article
    Tumors Are 3D. Shouldn't Your In Vitro Model Be? Learn More.
    PUBLICATIONSListed by the impact factor of the journal

    Uropathogenic Escherichia Coli Invade Luminal Prostate Cells via FimH-PPAP Receptor Binding

    Researchers developed a 2D mouse stem cell-derived prostate epithelial organoid model. In the organoid model, 5α-dihydrotestosterone promoted differentiation of basal into luminal cells, while transcriptomic analyses validated the model in comparison to 3D models and mouse prostate tissue.
    [Nature Microbiology]

    Full Article

    Targeting SUV4-20H Epigenetic Enzymes Enhances Topoisomerase II Poisoning in Prostate Cancer

    The authors demonstrated that inhibiting histone H4-lysine 20 methyltransferases SUV4-20H1 and SUV4-20H2 induces synthetic lethality in combination with the TOP2 poison etoposide in prostate cancer.
    [Cancer Research]

    Abstract

    Circular RNA-Based Therapy Targeting Metabolic Vulnerability of Fatty Acid Synthesis Overcomes Castration-Resistant Prostate Cancer

    Scientists identified circUTRN, an androgen receptor-inhibited circRNA that was upregulated following neoadjuvant hormonal therapy and downregulated in prostate cancer tissues.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    SOX4-Mediated Post-Transcriptional Suppression of PTEN via mir-106b∼25 Cluster Contributes to Prostate Cancer Aggressiveness

    Investigators revealed that SOX4 expression was increased in patients with prostate cancer with low PTEN levels, and the expression of SOX4 and PTEN was inversely correlated in patients with prostate cancer.
    [Molecular Cancer Research]

    Abstract

    PEAK1 Promotes Prostate Cancer Progression and Docetaxel Resistance by Mediating the Polarization of Tumor-Associated Macrophages

    Researchers investigated the role and mechanisms of pseudopodium-enriched atypical kinase (PEAK) 1 in prostate cancer progression and docetaxel resistance.
    [European Journal of Medical Research]

    Full Article

    TDP2 Drives Immune Evasion and Metastatic Progression in Prostate Cancer

    Investigators identified tyrosyl-DNA phosphodiesterase 2 (TDP2) as a key regulator within the tumor microenvironment and suggested its potential utility as both a prognostic biomarker and therapeutic target in prostate cancer.
    [PloS One]

    Full Article
    He needed a better model system. So he invented a new organoid. Watch James Wells' webinar.
    REVIEWS

    Breaking Barriers in Prostate Cancer: The mRNA Vaccine Breakthrough and What Comes Next

    The authors explore mRNA-based vaccines as a promising immunotherapy in prostate cancer. They discuss their mechanism of action, advantages in production and safety, and results from early clinical trials
    [NPJ Vaccines]

    AbstractGraphical Abstract

    Unraveling the Microbial Landscape in Prostate Cancer: Pathogenesis to Therapy

    Scientists examine microbes from the skin, oral cavity, gut, urinary tract, and the prostate cancer microenvironment, summarizing how these communities affect prostate cancer initiation, progression, and therapeutic response.
    [NPJ Biofilms and Microbiomes]

    Abstract
    INDUSTRY AND POLICY NEWS

    Alessa Therapeutics Announces FDA Fast Track Designation for Enolen, a First-of-Its-Kind Treatment for Localized Prostate Cancer

    Alessa Therapeutics announced that the US FDA has granted Fast Track designation for Enolen®, the Company’s lead product candidate for the treatment of low to intermediate risk, localized prostate cancer.
    [Alessa Therapeutics]

    Press Release

    Butterfly Medical Announces Completion of Pivotal Trial for Minimally Invasive Treatment of Benign Prostatic Hyperplasia

    Butterfly Medical announced the successful completion of the final 12-month follow-up for all patients in its international pivotal clinical study. The landmark study was designed to evaluate the safety and efficacy of the Butterfly Prostatic Retraction Device, a first-line interventional therapy for BPH.
    [Butterfly Medical (BioSpace)]

    Press Release
    FEATURED EVENT

    Autophagy in Stress, Development, and Disease

    March 15-20, 2026
    Ventura, California, United States

    > See All Events

    JOB OPPORTUNITIES

    Research Faculty – Urology

    Ohio State University – Columbus, Ohio, United States

    Researcher – Prostate Tumor Microenvironment

    UNIOVI – Spain

    Postdoctoral Research Associate – Cancer

    Washington University Medical Campus – St. Louis, Missouri, United States

    Researcher – Brain Organoid Biology

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Faculty Position – Experimental Hematology

    St Jude Children’s Research Hospital – Memphis, Tennessee, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2